| Autor: |
Joel, Isohookana, Kirsi-Maria, Haapasaari, Ylermi, Soini, Peeter, Karihtala |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Anticancer research. 36(1) |
| ISSN: |
1791-7530 |
| Popis: |
The role of the redox-regulating peroxiredoxin (Prx) enzymes I-VI in pancreatic carcinoma is poorly characterized.The expression of Prxs I, II, III, V and VI was immunohistochemically evaluated in benign pancreas and in 69 pancreatic adenocarcinoma samples.Cytoplasmic Prx I expression was significantly greater in cancer cells than in benign pancreas (p=0.002) and Prx I expression in adenocarcinoma cells was associated with a larger tumour (p=0.005). Stronger cytoplasmic Prx III expression was associated with node negativity (p=0.007) and better tumor differentiation (p=0.033). Greater cytoplasmic Prx V expression was associated with smaller tumours (p=0.029) and negative nodal status (p=0.003). Among patients with T3-4 tumours, stronger intensity of cytoplasmic Prx I was associated with longer relapse-free survival (p=0.041). In patients with tumours of T3-4 class only, cytoplasmic Prx VI expression was associated with longer disease-free survival (p=0.0037).Peroxiredoxins appear to be promising prognostic factors in cases of pancreatic adenocarcinoma, and this may be related to their potential as tumour suppressors. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
